Thu, May 29, 2025
Wed, May 28, 2025
Tue, May 27, 2025
[ Tue, May 27th 2025 ]: BBC
Carpet in the bathroom - yay or nay?
Mon, May 26, 2025
[ Mon, May 26th 2025 ]: Forbes
Is Science Slowing Down?
Sun, May 25, 2025
[ Sun, May 25th 2025 ]: BBC
Ready in 20: Tandoori hot naan pizza
Sat, May 24, 2025
Fri, May 23, 2025
Thu, May 22, 2025
[ Thu, May 22nd 2025 ]: BBC
Dan Biggar tests a smart rugby ball

GSK drug's new approval sets up competition with Dupixent

The article from STAT News dated May 23, 2025, discusses several significant developments in the biotech industry. Novo Nordisk and GSK have announced a collaboration to develop new treatments for obesity and diabetes, leveraging GSK's expertise in respiratory diseases. CRISPR Therapeutics has made strides in its prime editing technology, showing promising results in treating genetic disorders. Additionally, a new COPD treatment from Merus has shown efficacy in clinical trials, potentially offering a new option for patients. Lastly, Merck's Keytruda has been approved for use in combination with other therapies for certain types of cancer, expanding its application in oncology. These updates highlight the ongoing innovation and partnerships driving advancements in healthcare.

Read the Full STAT Article at:
[ https://www.statnews.com/2025/05/23/biotech-news-novo-gsk-crispr-prime-copd-merus-keytruda-cancer-the-readout/ ]